All PlansCoverageHigh impact
Voluntary nationwide recall: Brexafemme
UPMC Health Plan·Pharmacy, OB-GYN, Internal Medicine +1 more·Pharmacy
We identified it
Aug 7, 2026
Summary
Scynexis, Inc. has issued a voluntary nationwide recall of two lots of Brexafemme (ibrexafungerp tablets) due to potential cross-contamination with a non-antibacterial ß-lactam drug substance. Billing teams must immediately identify and flag any claims for affected lot numbers and coordinate with providers to halt dispensing and notify patients.
Action Required
Immediately: (1) Billing team must identify and flag any claims processed for Brexafemme (antifungal for vulvovaginal candidiasis treatment) in the pharmacy system. (2) Contact the pharmacy department to obtain the specific recalled lot numbers from the full recall text and cross-reference against dispensing records. (3) For any claims matching recalled lots, place claims on hold and notify the supervising provider. (4) Coordinate with pharmacy to issue patient notifications and arrange alternative antifungal therapy. (5) Do not process reimbursement for affected lot claims until clarification from the plan and provider. Failure to act may result in claims being denied for recalled medication or potential liability issues if patients experience adverse reactions from cross-contamination.